ME Therapeutics Holding (FRA:Q9T) NonCurrent Deferred Liabilities: €0.00 Mil (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:Q9T ME Therapeutics Holding Inc FRA:Q9T
14 GF Score
Price €0.88
! 1 Warning Sign
View Full Analysis

What is ME Therapeutics Holding NonCurrent Deferred Liabilities?

ME Therapeutics Holding FRA:Q9T 14 NonCurrent Deferred Liabilities is €0.00 Mil as of May. 2026. GuruFocus rates FRA:Q9T with a GF Score™ of 14/100. The stock has 1 warning sign investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

ME Therapeutics Holding's non-current deferred liabilities for the quarter that ended in May. 2026 was €0.00 Mil.

ME Therapeutics Holding NonCurrent Deferred Liabilities Related Terms

ME Therapeutics Holding NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for ME Therapeutics Holding's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ME Therapeutics Holding NonCurrent Deferred Liabilities Chart

ME Therapeutics Holding Annual Data
Trend Aug22 Aug23 Aug24 Aug25
NonCurrent Deferred Liabilities
0.00 0.00 0.00 0.00

ME Therapeutics Holding Quarterly Data
Aug22 Dec22 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:Q9T
14GF Score
ME Therapeutics Holding Inc FRA:Q9T
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of €0.00 Mil mean?
ME Therapeutics Holding (FRA:Q9T) has a NonCurrent Deferred Liabilities of €0.00 Mil as of May. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on ME Therapeutics Holding and its competitors.
Is ME Therapeutics Holding's NonCurrent Deferred Liabilities too high?
ME Therapeutics Holding's current NonCurrent Deferred Liabilities is €0.00 Mil. Overall, ME Therapeutics Holding has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does ME Therapeutics Holding's NonCurrent Deferred Liabilities compare to VRTX and REGN?
ME Therapeutics Holding's NonCurrent Deferred Liabilities of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on ME Therapeutics Holding and its competitors. ME Therapeutics Holding's current NonCurrent Deferred Liabilities is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ME Therapeutics Holding stock overvalued right now?
ME Therapeutics Holding (FRA:Q9T) has a current NonCurrent Deferred Liabilities of €0.00 Mil. The current NonCurrent Deferred Liabilities is €0.00 Mil. ME Therapeutics Holding's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For ME Therapeutics Holding (FRA:Q9T), the current NonCurrent Deferred Liabilities is €0.00 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ME Therapeutics Holding Business Description

Other Exchanges METX:Canada
Address 2665 East Mall, Room 249, Vancouver, BC, CAN, V6T 1Z4
ME Therapeutics Holding Inc is a preclinical stage biotechnology company working on cancer-fighting drugs in the field of Immuno Oncology, developing next-generation therapeutics targeting immune suppression in cancer. It is developing novel drugs that target myeloid cells to directly treat cancer and enhance the benefits of current Immuno Oncology drugs, such as checkpoint inhibitors in currently untreatable cancers. Immuno Oncology is a new area of cancer research that has been successful in treating previously untreatable cancers by targeting the immune system rather than the cancer directly, allowing a single drug to be used for multiple cancer types with mostly manageable side effects.
14GF Score

Get the complete analysis for FRA:Q9T

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.88
Price